Biologics

US Industry Study with Forecasts for 2015 & 2020

Study #2792 | September 2011 | $4900 | 316 pages
Table of Contents

EXECUTIVE SUMMARY

MARKET ENVIRONMENT
General ........................................... 4
Demographic Patterns ...................... 5
Macroeconomic Outlook .................. 9
Healthcare Trends .......................... 12
  National Health Expenditures ...... 13
Pharmaceutical Supply & Demand .......... 17
Pharmaceutical Shipments
  by Therapeutic Class ..................... 18
Patient Activity .............................. 20
Medical Conditions ....................... 23
  Acute Conditions ......................... 26
  Chronic Conditions ....................... 26
Animal Health Industry Outlook ..... 28
Technological Overview
  of Biologics ................................ 31
  Recombinant DNA Biologics ........... 32
  Biosimilars ................................ 33
Regulation .................................... 36
  Regulation of Human
    Biologic Therapies ...................... 36
  Regulation of Biosimilar
    Products .................................. 39
  Regulation of Biologics Research
    & Testing Products ..................... 40
  Regulation of Animal Biologics ....... 41

PRODUCTS
General ........................................... 42
Demand by Type ............................ 43
  Monoclonal Antibodies .................. 46
  Cancer Treatment ........................ 49
  Rheumatoid Arthritis ................... 50
  Macular Degeneration .................. 51
  Psoriasis .................................. 52
  Infectious Disease ...................... 53
  Other Applications ..................... 53

  Vaccines & Toxoids ...................... 54
  Vaccines for Human Health ............ 56
    Routine Immunizations ............... 57
    Influenza ................................ 58
    Therapeutic Vaccines ................. 58
    Other Vaccines ......................... 59
    Animal Vaccines ....................... 60
    Hormones ................................ 60
    Insulin .................................. 62
    Human Growth Hormone ............... 64
    Teriparatide ............................. 66
    Follicle-Stimulating Hormone ....... 66
    Estrogen ................................ 67
    Calcitonin ............................... 68
    Thyrotropin ................................ 68
    Corticotropin ............................ 69
    Other Hormones ......................... 69
    Growth Factors ......................... 70
    Erythropoietins ........................ 72
    Colony-Stimulating Factors .......... 73
    Bone Morphogenetic Proteins ....... 74
    Other Growth Factors .................. 75
    Immunomodulators ...................... 76
    Immunosuppressing Agents .......... 78
    Interferons ................................ 79
    Other Immunomodulators ............. 80
    Blood & Blood Products ............... 82
    Plasma & Plasma Fractions .......... 84
    Whole Blood .............................. 86
    Cellular Components .................. 86
    Enzymes .................................. 90
    Enzyme Replacement Therapies ...... 91
    Neuromodulators ....................... 94
    Digestive Enzymes ..................... 96
    Thrombolytics ............................ 98
    Diagnostics ................................ 99
    Other Enzymes ........................... 101
    Coagulation Factors ................... 102
    Antihemophilics ......................... 103
    Other Coagulation Factors .......... 105
    Other Biologics ......................... 106

APPLICATIONS
General ........................................... 109
Human Healthcare ......................... 110
Cancer .......................................... 114
Autoimmune Diseases .................... 119
Infectious Diseases ....................... 121
Blood Disorders ............................ 123
Diabetes ....................................... 126
  Other Conditions ......................... 128
Biologics for Other Uses ............... 131
  Animal Health ............................ 131
  Research & All Other
    Applications ............................. 132

INDUSTRY STRUCTURE
General ........................................... 134
  Market Share .............................. 136
  Competitive Strategies ................. 147
  Mergers & Acquisitions ................. 149
  Licensing & Related Agreements ...... 154
  Research & Development ............... 169
  Manufacturing ............................ 171
  Marketing & Distribution .............. 172

COMPANY PROFILES
Abbott Laboratories ....................... 175
  Alere Incorporated ...................... 179
Alexion Pharmaceuticals ............... 181
Allergan Incorporated .................... 182
American Red Cross ....................... 184
Amgen Incorporated ....................... 185
Aptalis Pharma ............................. 191
AstraZeneca plc ............................ 192
Baxter International ...................... 195
Bayer AG ...................................... 197
Biogen Idec .................................. 199
BioMarin Pharmaceutical ............... 200

(continued on following page)
Table of Contents

COMPANY PROFILES
(continued from previous page)

Blood Systems .................... 202
Bristol-Myers Squibb ............ 203
CSL Limited ...................... 206
EKR Therapeutics ............... 209
Eli Lilly ............................. 210
Emergent BioSolutions .......... 214
GlaxoSmithKline plc ........... 219
Halozyme Therapeutics ........ 225
Intercell AG ....................... 228
Ipsen ................................. 232
Johnson & Johnson .............. 234
Lonza Group ..................... 241
Lundbeck (H.) A/S .............. 245
Massachusetts Biologic
Laboratories ...................... 247
Medtronic Incorporated ....... 248
Merck & Company ............... 250
Merck KGaA ....................... 257
New York Blood Center ....... 259
Novartis AG ....................... 261
Novo Nordisk ...................... 268
Pfizer Incorporated ............. 270
Questcor Pharmaceuticals ..... 277
Roche Holding ................... 278
Sanofi-Aventis .................. 286
Shire plc ......................... 296
sigma-tau Group ................. 298
Solvay SA ......................... 300
Stryker Corporation ............ 301
Teva Pharmaceutical Industries .. 302
US WorldMeds ................... 305
ViaCyte Incorporated ........... 306
WiCell Research Institute .... 307
Other Companies
Mentioned in Study .......... 309

EXECUTIVE SUMMARY

1 Summary Table ................. 3

MARKET ENVIRONMENT

1 Population & Households ........ 8
2 Macroeconomic Indicators .... 12
3 National Health Expenditures by
  Type & Source of Payment ...... 16
4 Pharmaceutical Supply
  & Demand .......................... 17
5 Pharmaceutical Shipments
  by Therapeutic Class ........... 20
6 Patient Activity .................. 23
7 Medical Conditions ............. 25
8 Animal Population & Veterinary
  Health Expenditures .......... 30

PRODUCTS

1 Biologics Demand by Type .... 45
2 Monoclonal Antibodies
  Demand ........................... 49
3 Vaccines Demand ............... 56
4 Hormones Demand .............. 62
5 Growth Factors Demand ....... 71
6 Immunomodulators Demand ... 77
7 Blood & Blood Products
  Demand ........................... 84
8 Enzymes Demand ............... 91
9 Coagulation Factors Demand .. 103
10 Other Biologics Demand ...... 108

APPLICATIONS

1 Biologics Demand
  by Application ................. 110
2 Biologics Demand for
  Human Healthcare
  by Condition & Use .......... 112
3 Cancer Biologics Demand .... 115

4 Autoimmune Biologics
  Demand .......................... 121
5 Infectious Diseases
  Biologics Demand ............. 123
6 Blood Disorders
  Biologics Demand .......... 126
7 Diabetes Biologics Demand ... 128
8 Other Human Health
  Biologics Demand by
  Condition & Product ........ 130
9 Biologics Demand for
  Other Applications ........... 131

INDUSTRY STRUCTURE

1 US Biologics Sales
  by Company, 2010 ............ 135
2 Selected Acquisitions
  & Divestitures ................. 151
3 Selected Cooperative
  Agreements ..................... 156

List of Charts

PRODUCTS

1 Biologics Demand by
  Product Type, 2010 ........... 46

APPLICATIONS

1 Human Healthcare Biologics
  Demand by Condition
  & Use, 2010 .................... 113

INDUSTRY STRUCTURE

1 US Biologicals Market
  Share, 2010 .................... 138
Gains will be driven by dramatic shifts in production technology and an expansion in the number of targeted diseases, including cancer, diabetes and other serious medical conditions.

US demand to rise 6.5% annually through 2015

US demand for biologics is expected to grow 6.5 percent per year to $102 billion in 2015, driven by dramatic shifts in production technology and an expansion in the number of targeted diseases. New biologics are being developed for the treatment of cancer, diabetes and other serious medical conditions, many of which are seeing their incidence rise in the US population. While growth in market value will slow from the double-digit advances registered during the past decade, this is primarily a function of restrained pricing, which will mask to some extent continued robust gains in market penetration.

Monoclonal antibodies to remain key segment

Biologics such as insulin, vaccines and various blood products have been available for many years. However, the more recent introduction of recombinant DNA technology has allowed manufacturers to develop a wide range of new products with very specific applications. For example, monoclonal antibodies that destroy targeted antigens -- such as cancer cells -- can now be purified, cloned and introduced into patients to instigate immune responses. Of more than 40 brand-named monoclonal antibodies currently available in the US, 26 have received FDA approval since 2000, and 15 of the 26 since 2005. These products have quickly established themselves as effective therapies for many forms of cancer, macular degeneration, rheumatoid arthritis and other diseases. New antibodies are under intensive investigation, and are expected to be introduced to market during the forecast period.

US approval of biosimilars to spur new biologics

A growing global market for biosimilars (also known as follow-on biologics) is gaining momentum in response to the expiration of patents for a number of key biologics and consumer demand to reduce treatment costs. Europe has led the global regulatory process to make biosimilars available but to date US approvals have lagged behind those in the international community. The FDA has allowed only a few biosimilars for sale in the US, generally following procedures for small molecule generics. However, the FDA has announced plans to release new regulatory guidelines by the end of 2011 that will clarify the approval process for follow-on biologics. Once biosimilars can be approved for US sale, they are expected to make lower-cost biologic treatments more widely available, presenting a challenge to some longstanding proprietary products. The push for approval of biosimilars is also expected to spur the creation of new biologic products and applications.
**Erythropoietins**

Demand for erythropoietins (EPOs) is expected to decline through 2015 to $4.5 billion, restrained by the introduction of NESP, a novel erythropoietin-stimulating protein with a longer half-life and, consequently, lower dosage requirements. EPO has also been associated with increased risk of mortality among cancer patients.

EPO, also called hematopoietin or hemopoietin, regulates the production of red blood cells. Other less common functions of EPO are to stimulate brain response to neuronal injury and wound healing. EPO is available through recombinant DNA technology and is used to encourage the development of red blood cells in patients with anemia as a result of kidney disease, HIV or cancer treatments (chemotherapy or radiation). Exogenous EPO has also been used as a performance-enhancing drug or doping agent. It can often be detected in blood and urine tests because it is slightly different from the endogenous protein. Darbepoetin alfa was found in athletes in 2002 at the Winter Olympic Games, and has been associated with the Tour de France. An alternative to doping with EPO is athletic training at high altitudes, which also increases the number of red cells in the blood.

Erythropoietin has been associated in several studies with increased risk of death and tumor growth in cancer patients receiving it for chemotherapy-related anemia. In a separate randomized trial, erythropoietin was shown not to have changed the number of blood transfusions given to critically ill patients — a finding that surprised researchers. In March 2008, the FDA supported keeping exogenous erythropoietin by Amgen and Johnson & Johnson available for continued use by cancer patients. However, EPO has experienced declining demand since 2005, in part as a response to these findings. Also challenging demand for EPO is the development of NESP, a glycoprotein with anti-anemic characteristics and a longer half-life than erythropoietin. NESP is now used with patients in 72.
Sample Profile, Table & Forecast

COMPANY PROFILES

Biogen Idec Incorporated
133 Boston Post Road
Weston, MA 02493
781-464-2000
http://www.biogenidec.com

Revenues: $4.7 billion (2010)
US Revenues: $2.8 billion (2010)
Research and Development Expenditures: $1.2 billion (2010)
Employment: 4,850 (2010)

Key Products: monoclonal antibodies and immunomodulators

Biogen Idec develops and manufactures therapies for human oncology, neurology and immunology. It manufactures markets and licenses various products used to treat non-Hodgkin’s lymphoma, rheumatoid arthritis, Crohn’s disease, multiple sclerosis and psoriasis.

The Company participates in the US biologics industry through the production of monoclonal antibodies and immunomodulators. Biogen Idec’s primary monoclonal antibody offering is TYSABRI, which is used for the treatment of Crohn’s disease and relapsing forms of multiple sclerosis. TYSABRI, which is made at Biogen Idec’s Research Triangle Park, North Carolina facility, is being developed and co-marketed through an agreement between the Company and Elan Corporation plc (Ireland). In 2010, the Company’s US revenues from TYSABRI accounted for $253 million. The Company is also conducting research and development activities related to daclizumab, a monoclonal antibody targeted at relapsing forms of multiple sclerosis. In May 2010, the Company commenced a Phase 3 study of daclizumab. Biogen Idec is developing and commercializing this product through an agreement with Abbott Laboratories (Abbott Park, Illinois). In January

TABLE IV-3
CANCER BIOLOGICS DEMAND (million dollars)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Resident Population (million)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$ cancer biologics/capita</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer Biologics Demand</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monoclonal Antibodies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Growth Factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood &amp; Blood Products</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunomodulators</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccines &amp; Toxoids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Healthcare Biologics Demand</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

“Demand for cancer-related vaccines is forecast to grow 30 percent per year to exceed $2 billion in 2015. Vaccines, once the purview of prevention against infectious disease, are now under investigation for their use in preventing and treating several forms of cancer. Demand for cancer vaccines is expected to grow rapidly over the forecast period as these products are approved and develop their place in various market niches.”

--Section IV, pg. 117
Corporate Use License

Now every decision maker in your organization can act on the key intelligence found in all Freedonia studies. For an additional $2600, companies receive unlimited use of an electronic version (PDF) of the study. Place it on your intranet, e-mail it to coworkers around the world, or print it as many times as you like.

Click here to learn more about the Corporate Use License

Order Form

Biologics ................................................................. $4900

☐ Corporate Use License (add to study price) * $2600
☐ Additional Print Copies @ $600 each *

Total (including selected option) $ 

☐ Enclosed is my check (5% discount) drawn against a US bank and mailed directly to The Freedonia Group. For wire transfers please contact our customer service department at info@freedoniagroup.com. Credit cards accepted.

☐ Bill my company ☐ American Express ☐ MasterCard ☐ Visa

Name 
Title 
Company 
Division 
Street (No PO Box please)

City/State/Zip 
Country 

Phone 
Fax 
Email 

Credit Card # 

Expiration Date

Signature 

☐ Individual Use License Agreement

The undersigned hereby represents that the above captioned study will be used by only ______ individual(s) who are employees of the company and that the study will not be loaded on a network for multiple users. In the event that usage of the study changes, the Company will promptly notify Freedonia of such change and will pay to Freedonia the appropriate fee based on Freedonia’s standard fee schedule then in effect. Note: Entire company corporate use license, add $2600; one additional user, add $600; two additional users, add $1200; three additional users, add $1800.

Signature 

☐ Corporate Use License Agreement

The above captioned study may be stored on the company’s intranet or shared directory, available to company employees. Copies of the study may be made, but the undersigned represents that distribution of the study will be limited to employees of the company.

Signature
About The Freedonia Group

The Freedonia Group, Inc., is a leading international industry market research company that provides its clients with information and analysis needed to make informed strategic decisions for their businesses. Studies help clients identify business opportunities, develop strategies, make investment decisions and evaluate opportunities and threats. Freedonia research is designed to deliver unbiased views and reliable outlooks to assist clients in making the right decisions. Freedonia capitalizes on the resources of its proprietary in-house research team of experienced economists, professional analysts, industry researchers and editorial groups. Freedonia covers a diverse group of industries throughout the United States, the emerging China market, and other world markets. Industries analyzed by Freedonia include:

- Chemicals
- Plastics
- Life Sciences
- Packaging
- Building Materials
- Security & Electronics
- Industrial Components & Equipment
- Automotive & Transportation Equipment
- Household Goods
- Energy/Power Equipment

Freedonia Custom Research

Freedonia Custom Research delivers the same high quality, thorough and unbiased assessment of an industry or market as an industry study. Since the research initiative is based upon a company’s specific needs, companies harness Freedonia’s research capabilities and resources to answer unique questions. When you leverage the results of a Freedonia Custom Research engagement, you are able to obtain important answers to specific questions and issues associated with: mergers and acquisitions, new product launches/development, geographic expansion, entry into new markets, strategic business planning, and investment and funding decisions.

Freedonia Custom Research is ideal for companies seeking to make a strategic difference in the status quo and focus on future business growth. Working side by side with clients, Freedonia’s team is able to define a research project that is custom-tailored to answer specific questions and provide the basis from which a company can make informed business decisions.

Other Studies

World Nutraceutical Ingredients

This study analyzes the world nutraceutical ingredient industry. It presents historical demand data for the years 2000, 2005 and 2010, and forecasts for 2015 and 2020 by product (e.g., nutrients and minerals, vitamins, herbal and non-herbal extracts), world region and major country. The study also considers market environment factors, details industry structure, evaluates company market share and profiles industry players.

#2799 .......... November 2011 ............... $4900

Cosmeceuticals

US demand for cosmeceutical products is expected to increase 5.8 percent annually through 2015. Injectable and skin care products will see the fastest growth, based on anti-aging benefits. Among chemicals, antioxidants will remain the largest category, while botanicals continue to see the fastest gains. This study analyzes the $6.5 billion US cosmeceuticals industry, with forecasts for 2015 and 2020 by product and chemical. The study also evaluates company market share and profiles industry competitors.

#2758 .......... July 2011 ............... $4900

Excipients

US excipients demand will advance 3.9 percent yearly through 2015, driven by continued growth in US pharmaceutical production and the increasing importance of excipients in drug formulation. Polymers will remain the top-selling type based on their use as fillers and binders in tablets. Fillers and diluents will remain the leading application and grow the fastest. This study analyzes the $1.5 billion US excipients industry, with forecasts for 2015 and 2020 by product and application. The study also evaluates company market share and profiles industry players.

#2736 .......... May 2011 ............... $4800

World In Vitro Diagnostic Products

Global demand for in vitro diagnostic (IVD) products will increase 7.1 percent annually through 2015. The US, Western Europe and Japan will remain the dominant markets, while developing world demand grows the fastest. Molecular diagnostics, cellular analysis and pathology products will be the fastest growing technologies. This study analyzes the $43.8 billion world IVD product industry, with forecasts for 2015 and 2020 by product, application, world region and for 14 countries. The study also evaluates company market share and profiles 25 industry participants.

#2724 .......... March 2011 ............... $6100

Vaccines

US demand for vaccines will advance 5.6 percent annually through 2014, driven by the development of new vaccines to treat complex human diseases, such as cancer. Public health recommendations for adult and adolescent immunization will produce continued strong sales in this segment, which has reached the level of pediatric vaccines sales. This study analyzes the $10.8 billion US vaccines industry, with forecasts for 2014 and 2019 by product. It also evaluates company market share and profiles US industry competitors.

#2667 .......... August 2010 ............... $4700